Alkeus Pharmaceuticals, Inc.

Alkeus Pharmaceuticals, Inc.

Biotechnology Research

Cambridge, MA 6,959 followers

Transformation in Sight

About us

Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.

Website
http://www.alkeuspharma.com
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Cambridge, MA
Type
Privately Held
Founded
2010
Specialties
Biopharmaceuticals, Rare Disease, Inherited Retinal Disorders, Genetic Diseases, Retina, and Ophthalmology

Locations

Employees at Alkeus Pharmaceuticals, Inc.

Updates

Similar pages

Browse jobs

Funding